Literature DB >> 12546445

Management of choroidal neovascularization following laser photocoagulation for central serous chorioretinopathy.

Tae Wook Ha1, Don Il Ham, Se Woong Kang.   

Abstract

Little is known about the natural history and management of choroidal neovascularization (CNV) which developed as a complication of laser photocoagulation for central serous chorioretinopathy (CSC). We experienced two patients with CNV which developed after laser treatment for CSC. Submacular membranectomy was performed on both cases after the confirmation of subretinal CNV with optical coherence tomography. One patient received photodynamic therapy for recurrent CNV. The vision of both patients has been improved over 6 months of follow up. These cases suggest that active intervention, including submacular surgery, improves the visual prognosis of this condition.

Entities:  

Mesh:

Year:  2002        PMID: 12546445     DOI: 10.3341/kjo.2002.16.2.88

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  4 in total

1.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

2.  Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.

Authors:  Yoko Nomura; Ryo Obata; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2012-04-20       Impact factor: 2.447

3.  Indocyanine green angiography in chronic central serous chorioretinopathy.

Authors:  Urszula Gajdzik-Gajdecka; Mariola Dorecka; Ewa Nita; Anna Michalska; Joanna Miniewicz-Kurowska; Wanda Romaniuk
Journal:  Med Sci Monit       Date:  2012-02

4.  Laser-Induced Choroidal Neovascularizations: Clinical Study of 3 Cases.

Authors:  Wipada Laovirojjanakul; Thuss Sanguansak; Yosanan Yospaiboon; Supat Sinawat; Suthasinee Sinawat
Journal:  Case Rep Ophthalmol       Date:  2017-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.